PsychedelicNewsBreaks

ThursdayFeb 03, 2022 11:29 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and educational organization, MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use. “We are thrilled to welcome…

Continue Reading

TuesdayFeb 01, 2022 12:11 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program. Principal Investigator Dr. Matthew Johnson, Ph.D., professor of psychiatry and behavioral sciences at Johns Hopkins University, will lead the study that will assess the safety and efficacy of psilocybin-assisted…

Continue Reading

TuesdayFeb 01, 2022 11:10 am

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series

Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) a psychedelic drug company, has announced the speaker for the third webinar in its Psychedelics for Alcoholism series. The company has invited addiction specialist and world-renowned author Dr. Gabor Maté to talk on the effects of Alcohol Use Disorder, addition and trauma. The webinar will also include information about Clearmind's patented portfolio as an effective treatment for the disorder. A retired Vancouver physician and a member of the Order of Canada, Maté has written several books with his most recent book —  “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture” —…

Continue Reading

MondayJan 31, 2022 3:31 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing sector rife with opportunity. “Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (‘JHU’) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment… In 2022, Johnson…

Continue Reading

MondayJan 31, 2022 1:49 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event

Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to dealing with trauma. The special virtual event, slated to take place starting at 12 p.m. ET on Feb. 3, 2022, is open and free to all, with registration required. Renowned speaker and bestselling author Dr.…

Continue Reading

ThursdayJan 27, 2022 11:23 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will report financial results for its third quarter ended Dec. 31, 2021, on Thursday, Feb. 10, 2022. According to the announcement, a conference call will be held on the same day at 8:30 a.m. ET to discuss the results and recent business updates. Cybin’s Chief Executive Officer Doug Drysdale will host the call and, following prepared remarks, Drysdale and other members of the management team will be available to answer questions from participants. Interested parties should visit https://ibn.fm/quTwC to register for…

Continue Reading

MondayJan 24, 2022 12:36 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King's College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said…

Continue Reading

MondayJan 24, 2022 12:08 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Access of New Medicines, Treatment for Mental Health Conditions

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently announced its wholly owned ketamine infusion clinic chain, Ketamine Wellness Centers LLC (“KWC”), will open two new clinics in Salt Lake City, Utah, and Reno, Nevada, by February 2022. KWC, at that time, had cumulatively delivered over 60,000 treatments across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. A recent article reads, “Delic will open 13 ketamine infusion clinics across the country over the next 18 months, adding to the company’s existing portfolio, which comprises of 12 KWC clinics as well as two clinics operated by subsidiary…

Continue Reading

ThursdayJan 20, 2022 9:56 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website. According to the update, the new site conveys the company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics,” said Anthony Durkacz, interim CEO of FSD Pharma. “With some of the greatest minds in…

Continue Reading

WednesdayJan 19, 2022 1:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”). The notice was regarding Cybin’s patent application connected to its investigational deuterated psychedelic tryptamine compound, CYB004, for the potential treatment of anxiety disorders. “The receipt of this notice of allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the company’s dedication to the discovery and development of differentiated psychedelic-based…

Continue Reading